1. Drosophila melanogaster as a model organism for screening acetylcholinesterase reactivators.
- Author
-
Macedo PE, Batista JES, Souza LR, Dafre AL, Farina M, Kuca K, Posser T, Pinto PM, Boldo JT, and Franco JL
- Subjects
- Animals, Models, Animal, Insecticides toxicity, Cholinesterase Inhibitors toxicity, Drosophila melanogaster drug effects, Drosophila melanogaster enzymology, Cholinesterase Reactivators pharmacology, Molecular Docking Simulation, Chlorpyrifos toxicity, Acetylcholinesterase metabolism, Oximes pharmacology
- Abstract
The widely used insecticide chlorpyrifos (CP) is known to inhibit acetylcholinesterase (AChE) activity attributed to result in various neurological disorders and acetylcholine-dependent organ functions including heart, skeletal muscle, lung, gastrointestinal tract, and central nervous systems. Enzyme reactivators, such as oximes, are known to restore AChE activity and mitigate adverse effects. The identification of compounds that reactivate AChE constitute agents with important therapeutic beneficial effects in cases of pesticide poisoning. However, the screening of novel drugs using traditional models may raise ethical concerns. This study aimed to investigate the potential of Drosophila melanogaster as a model organism for screening AChE reactivators, with a focus on organophosphate poisoning. The efficacy of several oximes, including pralidoxime, trimedoxime, obidoxime, methoxime, HI-6, K027, and K048, against CP-induced AChE activity inhibition in D. melanogaster was determined in silico , in vitro , and in vivo experiments. Molecular docking studies indicated a strong interaction between studied oximes and the active-site gorge of AChE. Data showed that selected oximes (100 μM) are effective in the reactivation of AChE inhibited by CP (10 μM) in vitro . Finally, in vivo investigations demonstrated that selected oximes, pralidoxime and K048 (1.5 ppm), reversed the locomotor deficits, inhibition of AChE activity as well as lowered the mortality rates induced by CP (0.75 ppm). Our findings contribute to utilization of D. melanogaster as a robust model for determination of actions of identified new AChE inhibitory agents with more effective therapeutic properties that those currently in use in the clinical practice in treatment of AChE associated disorders.
- Published
- 2024
- Full Text
- View/download PDF